

## NATIONAL INSTITUTE FOR HEALTH AND CLINICAL EXCELLENCE

## Review Proposal Project

## NICE Technology Appraisal no. 114; Methadone and buprenorphine for managing opioid dependence

## Provisional matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Manufacturers/sponsors</u></p> <ul style="list-style-type: none"> <li>• AAH Pharmaceuticals (methadone)</li> <li>• Actavis UK (buprenorphine, methadone)</li> <li>• Arrow Generics (buprenorphine)</li> <li>• Auden McKenzie (methadone)</li> <li>• M &amp; A Pharmachem (methadone)</li> <li>• Martindale Pharma (methadone)</li> <li>• Morningside Healthcare (buprenorphine)</li> <li>• Pinewood Healthcare (methadone)</li> <li>• Rosemont Pharmaceuticals (methadone)</li> <li>• SNS Pharmaceuticals (methadone)</li> <li>• Schering-Plough Ltd (buprenorphine)</li> <li>• Teva UK (buprenorphine)</li> <li>• Thornton &amp; Ross (methadone)</li> <li>• Wockhardt UK (methadone)</li> </ul> <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> <li>• Addaction</li> <li>• Adfam</li> <li>• Alliance</li> <li>• Afiya Trust</li> <li>• Black Health Agency</li> <li>• Chinese National Healthy Living Centre</li> <li>• Counsel and Care</li> <li>• Equalities National Council</li> <li>• Families Anonymous UK</li> <li>• Lifeline</li> <li>• Muslim Council of Britain</li> <li>• Muslim Health Network</li> <li>• Rehabilitation for Addicted Prisoners Trust (RAPt)</li> <li>• Release</li> </ul>	<p><u>General</u></p> <ul style="list-style-type: none"> <li>• Board of Community Health Councils in Wales</li> <li>• British National Formulary</li> <li>• Care Quality Commission</li> <li>• Commissioning Support Appraisals Service</li> <li>• Department of Health, Social Services and Public Safety for Northern Ireland</li> <li>• HM Prison Service</li> <li>• Medicines and Healthcare products Regulatory Agency</li> <li>• National Association of Primary Care</li> <li>• National Treatment Agency for Substance Misuse (NTA)</li> <li>• NHS Alliance</li> <li>• NHS Commercial Medicines Unit</li> <li>• NHS Confederation</li> <li>• NHS Quality Improvement Scotland</li> <li>• Public Health Wales NHS Trust</li> <li>• Scottish Medicines Consortium</li> </ul> <p><u>Comparator manufacturers</u></p> <ul style="list-style-type: none"> <li>• None</li> </ul> <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> <li>• Action on Addiction</li> <li>• Centre for Research on Drugs and Health Behaviour (Imperial College)</li> <li>• Department of Addictive Behaviour and Psychological Medicine (St George's Hospital Medical School)</li> <li>• DrugScope</li> <li>• Independent Drug Monitoring Unit (IDMU)</li> <li>• MRC Clinical Trials Unit</li> <li>• National Addiction Centre (Institute of</li> </ul>

<b>Consultees</b>	<b>Commentators (no right to submit or appeal)</b>
<ul style="list-style-type: none"> <li>• South Asian Health Foundation</li> <li>• Specialised Healthcare Alliance</li> <li>• Turning Point</li> </ul> <p><u>Professional groups</u></p> <ul style="list-style-type: none"> <li>• Addiction Recovery Foundation</li> <li>• Association of Nurses in Substance Abuse</li> <li>• British Association for Psychopharmacology</li> <li>• British Association for Services to the Elderly</li> <li>• British Geriatrics Society</li> <li>• European Association for the Treatment of Addiction UK</li> <li>• Federation of Drug and Alcohol Professionals</li> <li>• National Drug Prevention Alliance</li> <li>• National Pharmaceutical Association</li> <li>• Pharmaceutical Services Negotiating Committee</li> <li>• Royal College of General Practitioners</li> <li>• Royal College of Nursing</li> <li>• Royal College of Physicians</li> <li>• Royal College of Psychiatrists (Addictions Faculty)</li> <li>• Royal Pharmaceutical Society</li> <li>• Royal Society of Medicine</li> <li>• Specialist Clinical Addiction Network (SCAN)</li> <li>• Substance Misuse Management in General Practice (SMMGP)</li> <li>• United Kingdom Clinical Pharmacy Association</li> <li>• UK Harm Reduction Alliance</li> </ul> <p><u>Others</u></p> <ul style="list-style-type: none"> <li>• Department of Health</li> <li>• Kingston PCT</li> <li>• NHS Manchester</li> <li>• Welsh Assembly Government</li> </ul>	<p>Psychiatry)</p> <ul style="list-style-type: none"> <li>• National Institute for Health Research</li> <li>• Policy Research Institute on Ageing and Ethnicity</li> <li>• Research Institute for the Care of Older People</li> <li>• Society for the Study of Addiction</li> </ul> <p><u>Assessment Group</u></p> <ul style="list-style-type: none"> <li>• Assessment Group tbc</li> <li>• National Institute for Health Research (NIHR) Health Technology Assessment Programme</li> </ul> <p><u>Associated Guideline Groups</u></p> <ul style="list-style-type: none"> <li>• National Collaborating Centre for Mental Health</li> </ul> <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> <li>• none</li> </ul>



NICE is committed to promoting equality and eliminating unlawful discrimination. Please let us know if we have missed any important organisations from the lists contained within the matrix and which organisations we should include who have a particular focus on relevant equality issues.

### **Definitions:**

#### Consultees

Organisations that accept an invitation to participate in the appraisal; the manufacturer(s) or sponsor(s) of the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Assembly Government and relevant NHS organisations in England.

Consultees can participate in the consultation on the draft scope, the Assessment Report and the Appraisal Consultation Document, they are invited to prepare a submission dossier and all non-manufacturers/sponsors consultee organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee. All consultees are given the opportunity to appeal against the Final Appraisal Determination (FAD).

#### Commentators

Organisations that engage in the appraisal process but that are not asked to prepare a submission dossier, and that receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; NHS Quality Improvement Scotland; the relevant National Collaborating Centre (a group commissioned by the Institute to develop clinical guidelines); other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Information Authority and NHS Purchasing and Supplies Agency, and the *British National Formulary*).

All non-manufacturers/sponsors commentator organisations can nominate clinical specialists and patient experts to present their personal views to the Appraisal Committee.

#### Assessment team

An independent academic group (commissioned by the National Institute for Health Research (NIHR) Health Technology Assessment Programme (HTA Programme) to assist in the appraisal) prepares an Assessment Report on the health technology (a review of the clinical and cost effectiveness of the technology(ies) based on a systematic review of the literature and a review of manufacturer and sponsor submission to the Institute).

---

<sup>1</sup> Non manufacturer consultees are invited to submit statements relevant to the group they are representing.